Tokyo, Japan

Takuya Makino

USPTO Granted Patents = 6 

 

Average Co-Inventor Count = 10.5

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2011-2025

Loading Chart...
Loading Chart...
6 patents (USPTO):

Title: Takuya Makino: Innovator in Pharmaceutical Chemistry

Introduction

Takuya Makino is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds with therapeutic applications. With a total of 6 patents to his name, Makino's work has the potential to impact various medical treatments.

Latest Patents

Among his latest patents is the invention of bicyclic 1,4-diazepanones and their therapeutic uses. These compounds are defined by a specific formula and include stereoisomers, tautomers, and pharmaceutically acceptable salts. The patent outlines methods for using these compounds to treat diseases and disorders that respond to the modulation of skeletal sarcomere contractility. This innovative approach highlights Makino's commitment to advancing medical science through his research.

Career Highlights

Takuya Makino has worked with notable companies in the pharmaceutical industry, including Astellas Pharma GmbH and Cytokinetics, Inc. His experience in these organizations has allowed him to collaborate with leading experts and contribute to groundbreaking research in drug development.

Collaborations

Some of his notable coworkers include Toshio Yamanaka and Bradley Paul Morgan. Their collaborative efforts have further enriched the research environment in which Makino operates.

Conclusion

Takuya Makino's contributions to pharmaceutical chemistry through his patents and collaborations demonstrate his dedication to innovation in medical treatments. His work continues to pave the way for advancements in the field, showcasing the importance of research and development in healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…